CareDx, Inc. (CDNA) intrinsic value & 10-year financials

CareDx, Inc. (CDNA) has a Graham intrinsic value of $30.89 per share. At $64.00 on Oct 17, 2026, the stock trades 107% above that value. Over the last 10 fiscal years revenue grew 28.2% a year to $379.8M, with an average return on invested capital of -49.5%.

Graham intrinsic value
$30.89
Share price (Oct 17, 2026)
$64.00
Price vs Graham value
107% above
Market cap
$3.4B
Revenue (FY2025)
$379.8M
Revenue growth (10-yr CAGR)
28.2%
ROIC (10-yr avg)
-49.5%
Free cash flow (FY2025)
—

CDNA 10-year financial history

Fiscal year Revenue Net income EPS (diluted) Free cash flow Operating margin ROIC
FY2025 $379.8M -$21.4M -$0.40 — -8.1% -11.3%
FY2024 $333.8M $52.5M $0.93 — 12.2% 16.4%
FY2023 $280.3M -$190.3M -$3.54 — -72.5% -69.9%
FY2022 $321.8M -$76.6M -$1.44 — -24.0% -30.3%
FY2021 $296.4M -$30.7M -$0.59 — -10.0% -19.3%
FY2020 $192.2M -$18.7M -$0.40 — -11.7% -19.2%
FY2019 $127.1M -$22.0M -$0.52 — -19.3% -47.6%
FY2018 $76.6M -$46.8M -$1.31 -$6.0M -20.3% -71.3%
FY2017 $48.3M -$55.5M -$2.38 -$14.5M -42.0% -105.6%
FY2016 $40.6M -$39.5M -$2.39 -$17.1M -91.9% -136.8%

Source: annual 10-K filings on SEC EDGAR. Figures in USD.

Executive summary

CareDx, Inc. is a consistent compounder, expanding top-line revenue at 28.2% annually over the past decade.

CareDx, Inc. has historically struggled to out-earn its cost of capital, averaging just -49.5% ROIC.

CareDx, Inc. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.

Benjamin Graham lens

Under Benjamin Graham's formula using SEC EDGAR fundamentals, CareDx, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $30.89 per share.

CDNA stock: frequently asked questions

What is the intrinsic value of CareDx, Inc. (CDNA) stock?

Using Benjamin Graham's revised formula, V = EPS × (8.5 + 2g) × 4.4 / Y, with reported diluted earnings per share, a 15.0% normalized growth rate (capped at 15%) and a 5.1% AAA corporate bond yield, CDNA's intrinsic value is about $30.89 per share.

Is CDNA stock undervalued?

At $64.00 (close on Oct 17, 2026), CDNA trades 107% above its Graham value of $30.89. On Graham's terms the shares look fully priced. A formula is a starting point for research, not a recommendation.

How fast has CareDx, Inc. grown?

Revenue went from $40.6M in fiscal 2016 to $379.8M in fiscal 2025, a compound annual growth rate of 28.2%. Net income was -$21.4M in fiscal 2025.

What is CDNA's return on invested capital?

Average ROIC over the last 10 fiscal years was -49.5%, and average return on equity was -124.0%. Sustained ROIC above about 15% usually points to a durable competitive advantage.

Where does this CDNA data come from?

From CareDx, Inc.'s annual 10-K filings on SEC EDGAR, most recently filed Jul 30, 2026. Prices are end-of-day snapshots; valuations are formula outputs, not investment advice.

Similar medical laboratories stocks